Hutchison China MediTech Limited (NASDAQ:HCM) was downgraded by equities researchers at BidaskClub from a “buy” rating to a “hold” rating in a research report issued on Thursday.

Separately, Canaccord Genuity set a $30.00 price objective on Hutchison China MediTech Limited and gave the company a “buy” rating in a research note on Thursday, May 18th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $28.00.

Shares of Hutchison China MediTech Limited (NASDAQ:HCM) traded down 0.52% during midday trading on Thursday, reaching $25.10. 3,380 shares of the company’s stock were exchanged. Hutchison China MediTech Limited has a 12 month low of $10.61 and a 12 month high of $26.07.

ILLEGAL ACTIVITY NOTICE: “Hutchison China MediTech Limited (HCM) Downgraded to “Hold” at BidaskClub” was published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/14/hutchison-china-meditech-limited-hcm-downgraded-to-hold-at-bidaskclub.html.

A number of hedge funds have recently bought and sold shares of the business. Schroder Investment Management Group grew its holdings in Hutchison China MediTech Limited by 6.8% during the 1st quarter. Schroder Investment Management Group now owns 976,364 shares of the company’s stock valued at $20,084,000 after buying an additional 62,045 shares in the last quarter. Wellington Management Group LLP grew its holdings in Hutchison China MediTech Limited by 7.4% during the 1st quarter. Wellington Management Group LLP now owns 510,826 shares of the company’s stock valued at $10,190,000 after buying an additional 35,053 shares in the last quarter. Matthews International Capital Management LLC grew its holdings in Hutchison China MediTech Limited by 159.7% during the 1st quarter. Matthews International Capital Management LLC now owns 263,400 shares of the company’s stock valued at $5,255,000 after buying an additional 161,971 shares in the last quarter. JPMorgan Chase & Co. purchased a new position in Hutchison China MediTech Limited during the 2nd quarter valued at about $5,102,000. Finally, Baillie Gifford & Co. grew its holdings in Hutchison China MediTech Limited by 6.1% during the 2nd quarter. Baillie Gifford & Co. now owns 167,547 shares of the company’s stock valued at $3,905,000 after buying an additional 9,655 shares in the last quarter. 4.06% of the stock is owned by institutional investors and hedge funds.

Hutchison China MediTech Limited Company Profile

Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.

Receive News & Ratings for Hutchison China MediTech Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech Limited and related companies with MarketBeat.com's FREE daily email newsletter.